应用肺超声鉴别2019冠状病毒病(COVID-19)肺炎与社区获得性肺炎
本研究纳入12例COVID-19患者和20例社区获得性肺炎(CAP)患者行肺超声检查,采用改良Buda评分系统评估COVID-19严重程度与疗效,并与HRCT Warrick评分做相关性分析。COVID-19与CAP的超声特征(病变范围、肺部征象及肺炎相关并发症)差异有统计学意义(p<0.05或0.001);MLUS评分与HRCT Warrick评分呈正相关(r=0.54,p=0.048)。
要点
- COVID-19常见胸膜线增厚(12/12)、模糊(9/12)、不连续(6/12)及部分弥漫B线(12/12)。
- COVID-19与CAP在病变范围、肺部征象及肺炎相关并发症上差异有统计学意义。
- MLUS评分与HRCT Warrick评分呈正相关(r=0.54,p=0.048),可用于评估COVID-19严重程度及疗效。
关键影像表现/征象
- COVID-19超声特征包括胸膜线增厚(12/12)、模糊(9/12)、不连续(6/12)。
- COVID-19可见火箭征(4/12)、部分弥漫B线(12/12)、完全弥漫B线(10/12)、瀑布征(4/12)。
- COVID-19可见C线征(5/12)、胸腔积液(1/12)及肺气球征(Am线,1/12),后两者少见。
- COVID-19与CAP在病变范围、肺部征象及肺炎相关并发症上的超声特征差异有统计学意义(p<0.05或0.001)。
诊断标准与关键数值
- MLUS评分随COVID-19严重程度增加而升高(p=0.006)。
- HRCT Warrick评分随COVID-19严重程度增加而升高(p=0.015)。
- 中型COVID-19的MLUS评分为29.00(25.75-37.50),与重型43.00(38.75-47.25)比较p=0.022,与危重型47.50(44.25-50.00)比较p=0.002,差异有统计学意义。
- MLUS评分与HRCT Warrick评分呈正相关(r=0.54,p=0.048)。
- 5例重型或危重型COVID-19患者病情改善后,MLUS评分(Z=2.61,p=0.009)和HRCT Warrick评分(Z=2.63,p=0.009)均显著下降。
临床应用与阅片要点
- 肺超声可用于观察COVID-19的胸膜线异常、B线分布及C线征等征象。
- 改良Buda评分系统(MLUS评分)可用于评估COVID-19的严重程度及治疗后的变化。
- COVID-19患者胸腔积液(1/12)和肺气球征(Am线,1/12)少见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
To investigate the feasibility of lung ultrasound in evaluating coronavirus disease 2019 (COVID-19) and distinguish the sonographic features between COVID-19 and community-acquired pneumonia (CAP), a total of 12 COVID-19 patients and 20 CAP patients were selected and underwent lung ultrasound. The modified Buda scoring system for interstitial lung disease was used to evaluate the severity and treatment effect of COVID-19 on ultrasonography. The differences between modified lung ultrasound (MLUS) score and high-resolution computed tomography (HRCT) Warrick score were analyzed to evaluate their correlation. COVID-19 showed the following sonographic features: thickening (12/12), blurred (9/12), discontinuous (6/12) pleural line; rocket sign (4/12), partially diffused B-line (12/12), completely diffused B-line (10/12), waterfall sign (4/12); C-line sign (5/12); pleural effusion (1/12) and pulmonary balloon (Am line, 1/12). The last two features were rarely seen. Differences of ultrasonic features, including lesion range, lung signs and pneumonia-related complications, between COVID-19 and CAP were statistically significant (p˂ 0.05 or 0.001). MLUS scores (p = 0.006) and HRCT Warrick scores (p = 0.015) increased as the severity of COVID-19 increased. The differences between moderate (29.00 [25.75-37.50]) and severe (43.00 [38.75-47.25]) (p = 0.022) or between moderate and critical (47.50 [44.25-50.00]) (p = 0.002) type COVID-19 were statistically significant, compared with those between severe and critical types. Correlation between MLUS scores and HRCT Warrick scores was positive (r = 0.54, p = 0.048). MLUS scores (Z = 2.61, p = 0.009) and HRCT Warrick scores (Z = 2.63, p = 0.009) of five severe or critical COVID-19 patients significantly decreased as their conditions improved after treatment. The differences of sonographic features between COVID-19 and CAP patients were notable. The MLUS scoring system could be used to evaluate the severity and treatment effect of COVID-19.
引用
- Tan G, Lian X, Zhu Z, et al. Use of Lung Ultrasound to Differentiate Coronavirus Disease 2019 (COVID-19) Pneumonia From Community-Acquired Pneumonia. Ultrasound Med Biol. 2020. PMID: 32622684. doi:10.1016/j.ultrasmedbio.2020.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。